Skip to main content
Erschienen in:

01.10.2005 | Original Contribution

Utility of 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Managing Patients of Colorectal Cancer With Unexplained Carcinoembryonic Antigen Elevation at Different Levels

verfasst von: Feng-Yuan Liu, M.D., M.S., Jinn-Shiun Chen, M.D., Chung-Rong Changchien, M.D., Chien-Yuh Yeh, M.D., Shu-Hsing Liu, M.D., Kung-Chu Ho, M.D., Tzu-Chen Yen, M.D., Ph.D.

Erschienen in: Diseases of the Colon & Rectum | Ausgabe 10/2005

Einloggen, um Zugang zu erhalten

PURPOSE

Serum carcinoembryonic antigen elevation without detectable relapse during colorectal cancer follow-up presents a challenge. This study was designed to evaluate the utility of fluorine-18-labeled 2-fluoro-2-deoxy-D-glucose positron emission tomography in colorectal cancer patients with unexplained carcinoembryonic antigen elevation at different levels.

METHODS

Thirty-seven colorectal cancer patients referred for positron emission tomography after primary surgery who had serum carcinoembryonic antigen levels >5 ng/ml and negative or equivocal conventional imaging studies were analyzed. Patient status was determined by histopathology and/or clinical follow-up. Grouping as disease-free, potentially resectable, or advanced disease was performed. The management impact was defined as the percentage of patients with a true-positive positron emission tomography result.

RESULTS

The sensitivity, specificity, and accuracy of positron emission tomography for relapse detection were 89, 89, and 89 percent, respectively. The management impact was 68 percent. In 24 patients with carcinoembryonic antigen levels <25 ng/ml, positron emission tomography helped correct patient grouping in 20 patients (83 percent), including 8 in the disease-free group, 5 in the potentially resectable group, and 7 in the advanced-disease group. In 13 patients with carcinoembryonic antigen levels >25 ng/ml, positron emission tomography identified 8 patients in the advanced-disease group and 1 patient in the potentially resectable group but missed 2 patients with relapse and undergrouped 2 patients in the advanced-disease group as potentially resectable.

CONCLUSIONS

2-fluoro-2-deoxy-D-glucose positron emission tomography can help triage patients for appropriate management with unexplained carcinoembryonic antigen elevation <25 ng/ml. For patients with unexplained elevation of carcinoembryonic antigen >25 ng/ml, the utility of positron emission tomography is mainly to confirm the presence of advanced disease and occasionally to identify potentially resectable lesions.
Literatur
1.
Zurück zum Zitat Desch, CE, Benson, AB,3rd, Smith, TJ, et al. 1999Recommended colorectal cancer surveillance guidelines by the American Society of Clinical OncologyJ Clin Oncol17131221PubMed Desch, CE, Benson, AB,3rd, Smith, TJ,  et al. 1999Recommended colorectal cancer surveillance guidelines by the American Society of Clinical OncologyJ Clin Oncol17131221PubMed
2.
Zurück zum Zitat Goldberg, RM, Fleming, TR, Tangen, CM, et al. 1998Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resectionAnn Intern Med1292735PubMed Goldberg, RM, Fleming, TR, Tangen, CM,  et al. 1998Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resectionAnn Intern Med1292735PubMed
3.
Zurück zum Zitat Tepper, JE, O’Connell, M, Hollis, D, Niedzwiecki, D, Cooke, E, Mayer, RJ 2003Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114J Clin Oncol2136238CrossRefPubMed Tepper, JE, O’Connell, M, Hollis, D, Niedzwiecki, D, Cooke, E, Mayer, RJ 2003Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114J Clin Oncol2136238CrossRefPubMed
4.
Zurück zum Zitat Rosen, M, Chan, L, Beart, RW,Jr, Vukasin, P, Anthone, G 1998Follow-up of colorectal cancer: a meta-analysisDis Colon Rectum41111626PubMed Rosen, M, Chan, L, Beart, RW,Jr, Vukasin, P, Anthone, G 1998Follow-up of colorectal cancer: a meta-analysisDis Colon Rectum41111626PubMed
5.
Zurück zum Zitat Pfister, DG, Benson, AB,3rd, Somerfield, MR 2004Surveillance strategies after curative treatment of colorectal cancerN Engl J Med350237582CrossRefPubMed Pfister, DG, Benson, AB,3rd, Somerfield, MR 2004Surveillance strategies after curative treatment of colorectal cancerN Engl J Med350237582CrossRefPubMed
6.
Zurück zum Zitat Benson, AB,3rd, Desch, CE, Flynn, PJ, et al. 20002000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelinesJ Clin Oncol1835868PubMed Benson, AB,3rd, Desch, CE, Flynn, PJ,  et al. 20002000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelinesJ Clin Oncol1835868PubMed
7.
Zurück zum Zitat Minton, JP, Hoehn, JL, Gerber, DM, et al. 1985Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer studyCancer55128490PubMed Minton, JP, Hoehn, JL, Gerber, DM,  et al. 1985Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer studyCancer55128490PubMed
8.
Zurück zum Zitat Moertel, CG, Fleming, TR, Macdonald, JS, Haller, DG, Laurie, JA, Tangen, C 1993An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancerJAMA2709437CrossRefPubMed Moertel, CG, Fleming, TR, Macdonald, JS, Haller, DG, Laurie, JA, Tangen, C 1993An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancerJAMA2709437CrossRefPubMed
9.
Zurück zum Zitat McCall, JL, Black, RB, Rich, CA, et al. 1994The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancerDis Colon Rectum3787581CrossRefPubMed McCall, JL, Black, RB, Rich, CA,  et al. 1994The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancerDis Colon Rectum3787581CrossRefPubMed
10.
Zurück zum Zitat Engaras, B 2003Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivityDis Colon Rectum4631321CrossRefPubMed Engaras, B 2003Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivityDis Colon Rectum4631321CrossRefPubMed
11.
Zurück zum Zitat Fletcher, RH 1986Carcinoembryonic antigenAnn Intern Med1046673PubMed Fletcher, RH 1986Carcinoembryonic antigenAnn Intern Med1046673PubMed
12.
Zurück zum Zitat Flanagan, FL, Dehdashti, F, Ogunbiyi, OA, Kodner, IJ, Siegel, BA 1998Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancerAnn Surg22731923CrossRefPubMed Flanagan, FL, Dehdashti, F, Ogunbiyi, OA, Kodner, IJ, Siegel, BA 1998Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancerAnn Surg22731923CrossRefPubMed
13.
Zurück zum Zitat Ruhlmann, J, Schomburg, A, Bender, H, et al. 1997Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practiceDis Colon Rectum401195204CrossRefPubMed Ruhlmann, J, Schomburg, A, Bender, H,  et al. 1997Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practiceDis Colon Rectum401195204CrossRefPubMed
14.
Zurück zum Zitat Flamen, P, Stroobants, S, Cutsem, EV, et al. 1999Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancerJ Clin Oncol17894901PubMed Flamen, P, Stroobants, S, Cutsem, EV,  et al. 1999Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancerJ Clin Oncol17894901PubMed
15.
Zurück zum Zitat Zervos, EE, Badgwell, BD, Burak, WE, Arnold, MW, Martin, EW 2001Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workupSurgery13063644CrossRefPubMed Zervos, EE, Badgwell, BD, Burak, WE, Arnold, MW, Martin, EW 2001Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workupSurgery13063644CrossRefPubMed
16.
Zurück zum Zitat Kalff, V, Hicks, RJ, Ware, RE, Hogg, A, Binns, D, McKenzie, AF 2002The clinical impact 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective studyJ Nucl Med434929PubMed Kalff, V, Hicks, RJ, Ware, RE, Hogg, A, Binns, D, McKenzie, AF 2002The clinical impact 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective studyJ Nucl Med434929PubMed
17.
Zurück zum Zitat Simo, M, Lomena, F, Setoain, J, et al. 2002FDG-PET improves the management of patients with suspected recurrence of colorectal cancerNucl Med Commun2397582CrossRefPubMed Simo, M, Lomena, F, Setoain, J,  et al. 2002FDG-PET improves the management of patients with suspected recurrence of colorectal cancerNucl Med Commun2397582CrossRefPubMed
19.
Zurück zum Zitat Gambhir, SS, Czernin, J, Schwimmer, J, Silverman, DH, Coleman, RE, Phelps, ME 2001A tabulated summary of the FDG PET literatureJ Nucl Med421S93PubMed Gambhir, SS, Czernin, J, Schwimmer, J, Silverman, DH, Coleman, RE, Phelps, ME 2001A tabulated summary of the FDG PET literatureJ Nucl Med421S93PubMed
20.
Zurück zum Zitat Schluter, B, Bohuslavizki, KH, Beyer, W, Plotkin, M, Buchert, R, Clausen, M 2001Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scanJ Nucl Med42716PubMed Schluter, B, Bohuslavizki, KH, Beyer, W, Plotkin, M, Buchert, R, Clausen, M 2001Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scanJ Nucl Med42716PubMed
21.
Zurück zum Zitat Chang, TC, Law, KS, Hong, JH, et al. 2004Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II studyCancer10116471CrossRefPubMed Chang, TC, Law, KS, Hong, JH,  et al. 2004Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II studyCancer10116471CrossRefPubMed
22.
Zurück zum Zitat Bristow, RE, Carmen, M, Pannu, HK, et al. 2003Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CTGynecol Oncol9051928CrossRefPubMed Bristow, RE, Carmen, M, Pannu, HK,  et al. 2003Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CTGynecol Oncol9051928CrossRefPubMed
23.
Zurück zum Zitat Siggelkow, W, Rath, W, Buell, U, Zimny, M 2004FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancerEur J Nucl Med Mol Imaging31S11824CrossRefPubMed Siggelkow, W, Rath, W, Buell, U, Zimny, M 2004FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancerEur J Nucl Med Mol Imaging31S11824CrossRefPubMed
24.
Zurück zum Zitat Cook, GJ, Maisey, MN, Fogelman, I 1999Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionineEur J Nucl Med Mol Imaging26136378CrossRef Cook, GJ, Maisey, MN, Fogelman, I 1999Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionineEur J Nucl Med Mol Imaging26136378CrossRef
25.
Zurück zum Zitat Tatlidil, R, Jadvar, H, Bading, JR, Conti, PS 2002Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findingsRadiology2247837PubMed Tatlidil, R, Jadvar, H, Bading, JR, Conti, PS 2002Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findingsRadiology2247837PubMed
26.
Zurück zum Zitat Tanaka, T, Kawai, Y, Kanai, M, Taki, Y, Nakamoto, Y, Takabayashi, A 2002Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancerAm J Surg1844336CrossRefPubMed Tanaka, T, Kawai, Y, Kanai, M, Taki, Y, Nakamoto, Y, Takabayashi, A 2002Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancerAm J Surg1844336CrossRefPubMed
27.
Zurück zum Zitat Berger, KL, Nicholson, SA, Dehdashti, F, Siegel, BA 2000FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic featuresAJR Am J Roentgenol17410058PubMed Berger, KL, Nicholson, SA, Dehdashti, F, Siegel, BA 2000FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic featuresAJR Am J Roentgenol17410058PubMed
28.
Zurück zum Zitat Lonneux, M, Reffad, AM, Detry, R, Kartheuser, A, Gigot, JF, Pauwels, S 2002FDG-PET improves the staging and selection of patients with recurrent colorectal cancerEur J Nucl Med Mol Imaging2991521CrossRefPubMed Lonneux, M, Reffad, AM, Detry, R, Kartheuser, A, Gigot, JF, Pauwels, S 2002FDG-PET improves the staging and selection of patients with recurrent colorectal cancerEur J Nucl Med Mol Imaging2991521CrossRefPubMed
29.
Zurück zum Zitat Bast, RC,Jr, Ravdin, P, Hayes, DF, et al. 20012000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical OncologyJ Clin Oncol19186578PubMed Bast, RC,Jr, Ravdin, P, Hayes, DF,  et al. 20012000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical OncologyJ Clin Oncol19186578PubMed
30.
Zurück zum Zitat Wang, JY, Tang, R, Chiang, JM 1994Value of carcinoembryonic antigen in the management of colorectal cancerDis Colon Rectum372727CrossRefPubMed Wang, JY, Tang, R, Chiang, JM 1994Value of carcinoembryonic antigen in the management of colorectal cancerDis Colon Rectum372727CrossRefPubMed
31.
Zurück zum Zitat Slentz, K, Senagore, A, Hibbert, J, Mazier, WP, Talbott, TM 1994Can preoperative and postoperative CEA predict survival after colon cancer resection?Am Surg6052832PubMed Slentz, K, Senagore, A, Hibbert, J, Mazier, WP, Talbott, TM 1994Can preoperative and postoperative CEA predict survival after colon cancer resection?Am Surg6052832PubMed
32.
Zurück zum Zitat Park, YJ, Park, KJ, Park, JG, Lee, KU, Choe, KJ, Kim, JP 1999Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated casesWorld J Surg237216PubMed Park, YJ, Park, KJ, Park, JG, Lee, KU, Choe, KJ, Kim, JP 1999Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated casesWorld J Surg237216PubMed
33.
Zurück zum Zitat Fong, Y, Fortner, J, Sun, RL, Brennan, MF, Blumgart, LH 1999Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive casesAnn Surg23030921CrossRefPubMed Fong, Y, Fortner, J, Sun, RL, Brennan, MF, Blumgart, LH 1999Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive casesAnn Surg23030921CrossRefPubMed
34.
Zurück zum Zitat Penna, C, Nordinger, B 2002Surgery of liver metastases from colorectal cancer: new promisesBr Med Bull6412740CrossRefPubMed Penna, C, Nordinger, B 2002Surgery of liver metastases from colorectal cancer: new promisesBr Med Bull6412740CrossRefPubMed
35.
Zurück zum Zitat Kato, T, Yasui, K, Hirai, T, et al. 2003Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutionsDis Colon Rectum46S2231PubMed Kato, T, Yasui, K, Hirai, T,  et al. 2003Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutionsDis Colon Rectum46S2231PubMed
36.
Zurück zum Zitat Saito, Y, Omiya, H, Kohno, K, et al. 2002Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessmentJ Thorac Cardiovas Surg124100713CrossRef Saito, Y, Omiya, H, Kohno, K,  et al. 2002Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessmentJ Thorac Cardiovas Surg124100713CrossRef
37.
Zurück zum Zitat Cady, B, Jenkins, RL, Steele, GD,Jr, et al. 1998Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcomeAnn Surg22756671CrossRefPubMed Cady, B, Jenkins, RL, Steele, GD,Jr,  et al. 1998Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcomeAnn Surg22756671CrossRefPubMed
38.
Zurück zum Zitat Schneebaum, S, Arnold, MW, Young, D, et al. 1993Role of carcinoembryonic antigen in predicting respectability of recurrent colorectal cancerDis Colon Rectum368105CrossRefPubMed Schneebaum, S, Arnold, MW, Young, D,  et al. 1993Role of carcinoembryonic antigen in predicting respectability of recurrent colorectal cancerDis Colon Rectum368105CrossRefPubMed
39.
Zurück zum Zitat Kievit, J 2002Follow-up of patients with colorectal cancer: numbers needed to test and treatEur J Cancer3898699CrossRefPubMed Kievit, J 2002Follow-up of patients with colorectal cancer: numbers needed to test and treatEur J Cancer3898699CrossRefPubMed
Metadaten
Titel
Utility of 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Managing Patients of Colorectal Cancer With Unexplained Carcinoembryonic Antigen Elevation at Different Levels
verfasst von
Feng-Yuan Liu, M.D., M.S.
Jinn-Shiun Chen, M.D.
Chung-Rong Changchien, M.D.
Chien-Yuh Yeh, M.D.
Shu-Hsing Liu, M.D.
Kung-Chu Ho, M.D.
Tzu-Chen Yen, M.D., Ph.D.
Publikationsdatum
01.10.2005
Erschienen in
Diseases of the Colon & Rectum / Ausgabe 10/2005
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-005-0097-6

Weitere Artikel der Ausgabe 10/2005

Diseases of the Colon & Rectum 10/2005 Zur Ausgabe

OriginalPaper

Selected Abstracts

Neu im Fachgebiet Chirurgie

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Vier Kriterien sprechen für ein erhöhtes Risiko nach Appendektomie

17.07.2024 Appendektomie Nachrichten

Um bei Kindern den Schweregrad einer Appendizitis und drohende Komplikationen richtig einzuschätzen, können sich Chirurginnen und Chirurgen auf die intraoperativen Kriterien des US-amerikanischen NSQIP Pediatric stützen.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

Hormonersatztherapie bei chronischem PTH-Mangel

16.07.2024 Schilddrüsenautonomie Nachrichten

Palopegteriparatid von Ascendis Pharma ist eine Hormonersatztherapie für Menschen mit chronischem Hypoparathyreoidismus, beispielsweise nach Schilddrüsenoperationen. Sie ermöglicht den meisten Patientinnen und Patienten Unabhängigkeit von der konventionellen Vitamin-D- und Kalziumsubstitution.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.